NYSE:COR Cencora (COR) Stock Price, News & Analysis $275.01 +9.57 (+3.60%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$275.25 +0.24 (+0.09%) As of 05/22/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cencora Stock (NYSE:COR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cencora alerts:Sign Up Key Stats Today's Range$270.88▼$277.3950-Day Range$253.20▼$352.3952-Week Range$244.82▼$377.54Volume2.14 million shsAverage Volume2.30 million shsMarket Capitalization$53.51 billionP/E Ratio21.09Dividend Yield0.87%Price Target$380.25Consensus RatingModerate Buy Company Overview Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies. Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers. These services include commercialization support, market access and reimbursement consulting, patient hub and adherence programs, specialty pharmacy management, and clinical support services that help bring specialty and high-cost therapies to market and to patients efficiently. Cencora operates across multiple geographies with a network of distribution centers, specialty pharmacies and logistics facilities that serve hospitals, health systems, retailers, independent pharmacies, physician practices and manufacturers. The company’s infrastructure and service model are geared toward handling both high-volume commodity products and complex specialty medicines, including oncology, rare disease and biologic therapies. The company was formed through the rebranding of AmerisourceBergen in 2023 and is headquartered in Conshohocken, Pennsylvania. It is led by Steven H. Collis, who has served as chief executive officer since 2011. Cencora’s business model emphasizes integrated supply chain capabilities and services that support pharmaceutical manufacturers, payers and providers in delivering therapies to patients.AI Generated. May Contain Errors. Read More Cencora Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreCOR MarketRank™: Cencora scored higher than 97% of companies evaluated by MarketBeat, and ranked 22nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 12 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialCencora has a consensus price target of $380.25, representing about 38.3% upside from its current price of $275.01.Amount of Analyst CoverageCencora has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cencora's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth10.68% Earnings GrowthEarnings for Cencora are expected to grow by 10.68% in the coming year, from $17.79 to $19.69 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cencora is 21.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Cencora is 21.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.28.Price to Earnings Growth RatioCencora has a PEG Ratio of 1.27. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCencora has a P/B Ratio of 14.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cencora's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.68% of the float of Cencora has been sold short.Short Interest Ratio / Days to CoverCencora has a short interest ratio ("days to cover") of 3.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cencora has recently increased by 7.25%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldCencora has a dividend yield of 0.87%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthCencora has been increasing its dividend for 15 years.Dividend CoverageThe dividend payout ratio of Cencora is 18.40%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Cencora will have a dividend payout ratio of 12.19% next year. This indicates that Cencora will be able to sustain or increase its dividend.Read more about Cencora's dividend. News and Social Media3.6 / 5News Sentiment0.79 News SentimentCencora has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Cencora this week, compared to 8 articles on an average week.Search Interest18 people have searched for COR on MarketBeat in the last 30 days. This is an increase of 260% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cencora insiders have not sold or bought any company stock.Percentage Held by Insiders0.38% of the stock of Cencora is held by insiders.Percentage Held by Institutions97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cencora's insider trading history. Receive COR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COR Stock News HeadlinesCencora revises forecast for 2026, approves $2 billion share buybackMay 21 at 6:03 PM | reuters.comCencora Announces Updated Fiscal Year 2026 Financial OutlookMay 21 at 5:01 PM | businesswire.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.May 24 at 1:00 AM | Weiss Ratings (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - CORMay 21 at 3:33 PM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - CORMay 19, 2026 | globenewswire.comCOR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law FirmMay 18, 2026 | globenewswire.comCencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-RatingMay 18, 2026 | insidermonkey.comCencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-RatingMay 18, 2026 | finance.yahoo.comSee More Headlines COR Stock Analysis - Frequently Asked Questions How have COR shares performed this year? Cencora's stock was trading at $338.07 on January 1st, 2026. Since then, COR stock has decreased by 18.7% and is now trading at $275.0060. How were Cencora's earnings last quarter? Cencora, Inc. (NYSE:COR) released its earnings results on Wednesday, May, 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by $0.07. The company's revenue was up 3.9% on a year-over-year basis. Read the conference call transcript. Is Cencora buying back stock? Cencora's Board of Directors initiated a stock buyback plan on Thursday, May 21st 2026, which permits the company to buy back $2,000,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 3.9% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued. Does Cencora have any subsidiaries? The following companies are subsidiaries of Cencora: Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and more. Who are Cencora's major shareholders? Top institutional investors of Cencora include Bank of America Corp DE (2.13%), Amundi (0.80%), Dimensional Fund Advisors LP (0.80%) and Bessemer Group Inc. (0.62%). Insiders that own company stock include Walgreens Boots Alliance, Inc, Steven H Collis, Robert P Mauch, Robert P Mauch, Elizabeth S Campbell, Dermot Mark Durcan, Lazarus Krikorian, Silvana Battaglia, Gina Clark, Gina Clark, Leslie E Donato and Leslie E Donato. View institutional ownership trends. How do I buy shares of Cencora? Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cencora own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Broadcom (AVGO), Netflix (NFLX) and Tesla (TSLA). Company Calendar Record date for 3/2 Dividend2/13/2026Ex-Dividend for 3/2 Dividend2/13/2026Dividend Payable3/02/2026Last Earnings5/06/2026Record date for 6/1 Dividend5/15/2026Ex-Dividend for 6/1 Dividend5/15/2026Today5/24/2026Dividend Payable6/01/2026Next Earnings (Estimated)8/05/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 COR's financial health is in the Red zone, according to TradeSmith. COR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical Services Sub-IndustryHealth Care Distributors Current SymbolNYSE:COR CIK1140859 Webwww.amerisourcebergen.com Phone(610) 727-7000Fax800-640-5221Employees51,000Year Founded2001Price Target and Rating Average Price Target for Cencora$380.25 High Price Target$440.00 Low Price Target$331.00 Potential Upside/Downside+38.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$13.04 Trailing P/E Ratio21.09 Forward P/E Ratio15.46 P/E Growth1.27Net Income$1.55 billion Net Margins0.78% Pretax Margin1.07% Return on Equity135.20% Return on Assets4.20% Debt Debt-to-Equity Ratio3.40 Current Ratio0.95 Quick Ratio0.59 Sales & Book Value Annual Sales$321.33 billion Price / Sales0.17 Cash Flow$21.62 per share Price / Cash Flow12.72 Book Value$18.43 per share Price / Book14.92Miscellaneous Outstanding Shares194,560,000Free Float193,822,000Market Cap$53.51 billion OptionableOptionable Beta0.64 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:COR) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cencora, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cencora With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.